JB Chemicals & Pharmaceuticals ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced record revenue growth of 32% to Rs. 793 crore in Q3 FY23.  

 

Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 26% to Rs. 193 crore as compared to Rs. 153 crore. Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%.

 

Commenting on financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma said, “JB continues its growth journey delivering strong financial performance in the quarter. Our organic business outpaced the market, whereas our inorganic portfolio added to the upsides with better than anticipated momentum. Our inorganic strategy is built around growing the India business and increasing share in the chronic segment. During the quarter, we acquired the Razel franchise (Rosuvastatin and its combinations). This further strengthens our chronic presence, as we enter the ‘Statins’ category - the largest segment in cardiology. Our strong prescriber base and existing chronic teams will help in further growing the brand and drive operating leverage.” 

 

“The CMO business continued its revenue traction, while other parts of international business have also witnessed good growth. We are equally cautious about the inflationary environment and continue to build on productivity and cost optimization initiatives to enable us maintain our operating margins,” added Chopra. 

 

J.B. Pharma is a leading player in the hypertension segment. Besides its strong India presence, which accounts for the majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. 

 

Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges.